Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 162167-97-7 | MDL No. : | MFCD01317792 |
Formula : | C11H22N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WPWXYQIMXTUMJB-UHFFFAOYSA-N |
M.W : | 214.30 | Pubchem ID : | 2756483 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.91 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 64.11 |
TPSA : | 55.56 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.95 cm/s |
Log Po/w (iLOGP) : | 2.71 |
Log Po/w (XLOGP3) : | 0.92 |
Log Po/w (WLOGP) : | 1.21 |
Log Po/w (MLOGP) : | 1.15 |
Log Po/w (SILICOS-IT) : | 0.69 |
Consensus Log Po/w : | 1.34 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.48 |
Solubility : | 7.03 mg/ml ; 0.0328 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.67 |
Solubility : | 4.55 mg/ml ; 0.0212 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.33 |
Solubility : | 10.1 mg/ml ; 0.0471 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.7 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With hydrazine hydrate In ethanol at 20℃; for 24 h; | (2) Synthesis of tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate Hydrazine monohydrate (1 mL, 20.58 mmol) was added to an ethanol (20 mL) solution of the compound (1.45 g, 4.21 mmol) synthesised in (1), and the mixture was stirred at room temperature for 24 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was re-suspended in ethanol, and allowed to stand under ice-cooled conditions. After filtration, the filtrate was concentrated under reduced pressure to obtain the target (823 mg, 91 percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With triethylamine; In dichloromethane; at 0 - 20℃; for 70h; | Part A: Preparation of 3-(Benzyloxycarbonylaminomethyl)-piperidine-1-carboxylic Acid Tert-butyl Ester A solution of 3-aminomethylpiperidine-1-carboxylic acid tert-butyl ester (2.20 g, 10.3 mmol) in dichloromethane (40 mL) was treated with triethylamine (1.90 mL, 13.3 mmol) and stirred on an ice bath. A solution of benzyl chloroformate (1.90 mL, 13.3 mmol) in dichloromethane (10 mL) was added over 5 minutes. The mixture was stirred at room temperature for 70 hours. It was washed with 0.1 N aqueous hydrochloric acid, dried over sodium sulfate, and concentrated under vacuum to provide a colorless gum (3.58 g, quantitative) which was used without further purification. 1H NMR (300 MHz, CDCl3) delta 7.37 (m, 5H), 5.11 (s, 2H), 3.75 (m, 2H), 3.18 (m, 1H), 3.05 (m, 2H), 2.83 (m, 1H), 1.9-1.6 (m, 4H), 1.46 (s, 9H), 1.27 (m, 1H). |
55% | With triethylamine; In dichloromethane; at 0℃; for 16h; | 3-Aminomethyl-piperidine-l-carboxylic acid tert-butyl ester (3.6 g, 16.8 mmol)was dissolved in 42 mL anhydrous CH2CI2 under an N2 atmosphere and cooled in an ice water bath. Triethylamine (4.7 mL, 33.6 mmol) was added followed by the dropwise addition of benzyl chloroformate (3.55 mL, 25.2 mmol). After 16 hours, the reaction mixture was partitioned between CEbCli/B^Ojand separated, and the aqueous layer was extracted twice with CH2CI2. All of the organic extracts were combined, dried overNa2S04, filtered, and concentrated to a light yellow oil. Purification by silica gel chromatography using 97percent CH2Cl2/3percent MeOH gave the product as a clear colorless oil (55percent). LC/MS: m/z 349.3 (M+H)+ at 3.22 min (10percent-99percent CH3CN (0.035percent TFA)/H20 (0.05percent TFA)). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
A mixture of Example 270 (11 mg, 0.020 mmol), tert-butyl 3-(aminomethyl)-1-piperidinecarboxylate (5 mg, 0.024 mmol), and Na2CO3 (0.060 mmol, 6 mg) in dichloromethane (1 mL) and water (0.5 mL) was treated with a solution of tetramethylfluoroformadinium hexafluorophosphate (TFFH, 8 mg, 0.030 mmol) in dichloromethane (0.5 mL), stirred for 3 days at ambient temparature, treated with additional amine (12 mg, 0.056 mmol), stirred another day, treated with additional TFFH (30 mg, 0.11 mmol), and partitioned between dichloromethane and saturated NaHCO3. The combine organic phases were dried (Na2SO4), filtered, and concentrated. The residue was purified by reversed phase HPLC. The acetonitrile was removed under vacuum and the residue was lyophilized to provide the BOC-protected amine which was dissolved in dichloromethane (1 mL), triethylsilane (0.2 mL), and trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue was purified by reverse phase HPLC. The acetonitrile was removed under vacuum and the desired product was isolated by lyophylization (1.9 mg). LCMS m/e 595.2; Rt=2.67 min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium carbonate; fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate; In dichloromethane; water; at 20℃; for 4h; | [0704] A mixture of Example 270 (11 mg, 0.020 mmol), tert-butyl 3-(aminomethyl)-1-piperidinecarboxylate (5 mg, 0.024 mmol), and Na2CO3 (0.060 mmol, 6 mg) in dichloromethane (1 mL) and water (0.5 mL) was treated with a solution of tetramethylfluoroformadinium hexafluorophosphate (TFFH, 8 mg, 0.030 mmol) in dichloromethane (0.5 mL), stirred for 3 days at ambient temparature, treated with additional amine (12 mg, 0.056 mmol), stirred another day, treated with additional TFFH (30 mg, 0.11 mmol), and partitioned between dichloromethane and saturated NaHCO3. The combine organic phases were dried (Na2SO4), filtered, and concentrated. The residue was purified by reversed phase HPLC. The acetonitrile was removed under vacuum and the residue was lyophilized to provide the BOC-protected amine which was dissolved in dichloromethane (1 mL), triethylsilane (0.2 mL), and trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue was purified by reverse phase HPLC. The acetonitrile was removed under vacuum and the desired product was isolated by lyophylization (1.9 mg). LCMS m/e 595.2; Rt=2.67 min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
96% | With hydrogen;palladium 10% on activated carbon; In ethanol; under 3863.02 Torr; for 5h; | Part D: Preparation of 3-Aminomethylpiperidine-1-carboxylic Acid Tert-butyl Ester A mixture of 3-azidomethylpiperidine-1-carboxylic acid tert-butyl ester (5.0 g, 20.8 mmol), ethanol (125 mL) and 10percent palladium on charcoal (1.5 g) was shaken under a hydrogen atmosphere (60 psig) for 5 hours. The mixture was filtered. The filtrate was concentrated to provide a colorless oil (4.27 g, 96percent) which was used without further purification. 1H NMR (300 MHz, CDC13) delta 3.91 (b, 1H), 3.82 (dt, J=13, 4 Hz, 1H), 2.90 (m, 1H), 2.8-2.5 (m, 3H), 1.85 (m, 1H), 1.75 (s, 2H), 1.66 (m, 1H), 1.6-1.4 (m, 2H), 1.47 (s, 9H), 1.20 (m, 1H). Mass spec (AP+) m/z 215.2 (M+H+, 100percent). |
16.3 g (96%) | palladium-carbon; In methanol; | C. 3-(Aminomethyl)-1-piperidinecarboxylic acid, 1.1-dimethylethyl ester To a stirred solution of Part B azide (19.0 g, 79.2 mmol) in 250 mL of methanol under argon was added 10percentPd/C (3.80 g, 20percent based on the weight of Part B azide). The atmosphere was replaced with hydrogen by several vacuum-fill cycles. The mixture was stirred at room temperature for 15 h. The catalyst was filtered through a 4 muM polycarbonate film and rinsed with methanol (4*30 mL). The filtrate was concentrated in vacuo to give 16.3 g (96percent) of title amine. |
16.3 g (96%) | palladium-carbon; In methanol; | C. 3-(Aminomethyl)-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester To a stirred solution of Part B azide (19.0 g, 79.2 mmol) in 250 mL of methanol under argon was added 10percentPd/C (3.80 g, 20percent based on the weight of Part B azide). The atmosphere was replaced with hydrogen by several vacuum-fill cycles. The mixture was stirred at room temperature for 15 h. The catalyst was filtered through a 4 muM polycarbonate film and rinsed with methanol (4*30 mL). The filtrate was concentrated in vacuo to give 16.3 g (96percent) of title amine. |
With 5%-palladium/activated carbon; hydrogen; In methanol; for 9h; | tert-butyl 3-(aminomethyl)piperidine-1-carboxylate tert-butyl 3-(azidomethyl)piperidine-1-carboxylate (5.38 g, 22.40 mmol) was dissolved in MeOH (50 ml), and then Pd/C (5percent mol) was added, followed by stirring under H2 (gas) for 9 hours. After the completion of the reaction, the reaction mixture was filtered through celite, followed by filtration and concentration under reduced pressure, and then the next reaction was advanced without purification. 1H-NMR (300 MHz, CDCl3) delta 4.02-3.73 (m, 2H), 2.94-2.73 (m, 1H), 2.72-2.33 (m, 3H), 1.90-1.02 (m, 5H), 1.44 (s, 9H) | |
With palladium on activated charcoal; hydrogen; In methanol; at 20℃; for 9h; | [0306] Tert-Butyl 3- (azidomethyl) piperidine-1-carboxylate (5.38 g, 22.40 mmol) was dissolved in MeOH (50 ml), Pd / C (5percent mol) was added and the mixture was stirred at room temperature for 9 hours under H2 gas. After the completion of the reaction, the reaction solution was filtered through Celite, filtered, concentrated under reduced pressure, and the following reaction was carried out without purification |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; In dichloromethane; at -10 - 0℃; | 3-Aminomethyl-piperidine-1-carboxylic acid tert-butyl ester 1c (5.0 g, 23.4 mmol) in 20 mL CH2Cl2 was added dropwise to a cold (-10-->0° C.) solution of chloroacetylchloride (2.8 mL, 35 mmol, 1.5 equiv) and diisopropylethylamine (6.1 mL, 35 mmol, 1.5 equiv) in 60 mL CH2Cl2 under N2. After being left overnight (-10° C.-->rt), the mixture was diluted with ethyl acetate and washed briefly with water and brine, dried (Na2SO4), and concentrated to give 3-[(2-chloroacetylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 1d as a dark brown oil. The crude product was used without further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
84% | With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; DMF (N,N-dimethyl-formamide); at 20℃; | The mono HCl salt of EDC (0.86 g, 4.5 mmol, 1.5 equiv) was added to a suspension of 3-(5-(3,4-dimethoxy-phenyl)pyrimidin-2-yl)-propanoic acid (0.95 g, 3.3 mmol, 1.1 equiv), <strong>[162167-97-7]3-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester</strong> (0.64 g, 3.0 mmol), HOBT (0.61 g, 4.5 mmol, 1.5 equiv), and diisopropylethylamine (1.3 mL, 7. mmol, 2.5 equiv) in a 50 mL solvent (THF:DMF, 7:3). After stirring overnight at rt, the mixture was concentrated and the residue was dissolved in 50 mL ethyl acetate. The solution was poured into 50 mL of a saturated NaHCO3 solution and extracted thoroughly with ethyl acetate. The combined organic layers were washed with brine and water, dried (Na2SO4), and concentrated. The residue was purified by flash chromatography (0-->10percent MeOH in CHCl3). Clean fractions containing the desired product were combined and concentrated to give 3-({3-[5-(3,4-dimethoxy-phenyl)-pyrimidin-2-yl]-propionylamino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester (1.22 g, 84percent) as a dark brown solid. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydrogen sulfate; In water; for 2h; | Benzaldehyde (20.9 g, 197 mmol) was added to a solution of 3-aminomethylpiperidine 1b (22.5 g, 197 mmol) dissolved in toluene (anhydrous, 200 mL) in a 50 mL flask at rt under N2. A Dean-Stark apparatus and condenser were fitted, the reaction vessel well lagged, and the reaction mixture heated at a strong reflux for 3 h. (4.9 ml of water was collected). The mixture was cooled to rt and di-tert-butyl dicarbonate (47.4 g, 217 mmol, 1.1 equiv) was added portion-wise and the resulting solution was stirred at rt overnight. The mixture was concentrated and the resulting residue diluted with 250 mL of 1M NaHSO4. After stirring vigorously for no more than 2 h, the mixture was washed with ether to remove unwanted byproducts. The aqueous solution was then made strongly basic (pH 12) with NaOH and extracted thoroughly with ethyl acetate. The organic layer was washed with brine, dried with anhydrous Na2SO4, and concentrated to give 3-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester 1c as a colorless oil (33.8 g, 80percent), which was used directly without further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With lithium aluminium tetrahydride; In tetrahydrofuran; diethyl ether; at -78 - 27℃; for 0.5h; | A solution of tert-butyl 3-cyanopiperidine-1-carboxylate 62 (5.0 g, 23.00 mmol) in Ether (40 mL) was cooled to -78°C followed by drop wise addition of LAH (2.40 M solution in THF, 19.80 ml, 47.0 mmol). The resulting solution was then stirred for 30 mm. at RT. Reaction was monitored by TLC, reaction mixture was quenched with saturated NaOH solution at 0°C & reaction mixture was filtered through sodium sulfate, combined organic extracts were dried over Na2SO4 and concentrated to obtain crude compound (3.50 g, quantitative yield), which was carried forward as such for the next step. MS: 215.17 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With pyridine; In dichloromethane; at 25℃; for 2h; | Example 1; Preparation of 6-KK1 -l2-r6-(methvloxv)-1.5-naphthvridin-4-vnethvl)-3-piperidinvnmethvnamino)methvh-2/-/-pvrido[3.2-b1l'1.41thiazin-3(4H)-one; (a)2,2,2-trifluoro-A/-(3-piperidinylmethyl)acetamide; To a solution of 1,1-dimethylethyl 3-(aminomethyl)-1-piperidinecarboxylate (500mg, 2.3 mmol) in DCM (0.93 ml_) at 25 °C were added pyridine (0.57mL, 7.0 mmol)followed by a solution of TFAA (0.725ml, 5.13 mmol) in DCM (0.93 ml_) dropwise. After2 h, the reaction was quenched with ice water and extracted several times with DCM. Thecombined organic fractions were washed with NaOH solution, dried over Na2SO4 andconcentrated.The crude residue was dissolved in TFA (12.9 ml) and stirred at 25 °C. After 12h,the solution was concentrated yielding the trifluoroacetyl salt as an orange solid, that wasused without further purification: LC/MS (ES) m/e 211 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In toluene; for 16h;Heating / reflux; | tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate (3.00 g, 14.0 mmol) in toluene (20 ml)was added to 6-bromo-2-(2-methylphenyl)-4H-3,1-benzoxazin-4-one (3.69 g, 11.7 mmol) (step 1),and the solution was stirred at reflux for 16 h under a nitrogen atmosphere. The mixture wasconcentrated under reduced pressure and passed through a silica gel plug using EtOAc as eluent.Removal of the solvent under reduced pressure gave the intermediate as a yellow oil which wasused in the next step without further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | Step 2. Preparation of tert-butvl 3-f(6-bromo-2-isopropvl-4-oxoauinazolin-3(4H)-vl)methvl1piperidine-1-carboxylate; L-CH3^,Br'V T TH3CVCH3[215] A mixture of 6-bromo-2-isopropyl-4H-3,1-benzoxazin-4-one (18.8 g, 70 mmol) (step 1) and<strong>[162167-97-7]tert-butyl 3-(aminomethyl)piperidine-1-carboxylate</strong> (18 g, 84 mmol) in toluene was heated at refluxfor 4 h. After removal of the organic solvent under reduced pressure, ethylene glycol (25 mL) andLiOH (3.35 g, 140 mmol) were added, and the mixture was heated at 130°C for 5 h. After coolingto rt, water was added, and the mixture was extracted with DCM (3x). The combined organiclayers were washed with brine, dried over MgSO4, filtered, and concentrated under reducedpressure. The crude product was purified by silica gel chromatography (20percent ethyl acetate inhexane) to afford 15.5 g (48percent) of the product. ES-MS m/z 464.1 (MH+); HPLC RT (min) 4.01. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In toluene; at 80℃; for 16h; | Step 2. Preparation of tert-butvl 3-{r6-bromo-2-(2-methoxyphenvl)-4-oxoquinazolin-3(4H)-vl1methvl)piperidine-1-carboxylate; O CH3O^N"[276] To a dry 50 mL round-bottom flask was added 6-bromo-2-(2-methoxyphenyl)-4H-3,1 -71benzoxazin-4-one (1.50 g, 4.51 mmol) (step 1), followed by anhydrous toluene (10 ml_), and 3-aminomethyl-1-N-BOC-piperidine (1.16 g, 5.42 mmol). The mixture was heated to 80°C and wasstirred for 16 h under an atmosphere of N2. The mixture was concentrated under reducedpressure and purified by silica gel flash chromatography (100percent CH2CI2 ramping to 97percent CH2Cl2:3percent MeOH with 1percent Et3N). This gave the intermediate as a viscous light yellow oil. R( = 0.18 (95percentCH2CI2: 5percent MeOH); ES-MS m/z 547 (MH+, 75), 430 (46), 332 (39). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzotriazol-1-ol; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; In dichloromethane; at 20℃; for 22h; | To a solution of 1 ,1 -dimethylethyl 3-(aminomethyl)-1 -piperidinecarboxylate (0.54 g, 2.35 mmol) in CH2CI2 was added HOBt (0.38 g), Cbz-Leu (0.68 g) and EDC (0.54 g). The reaction was maintained at room temperature for 22 hours whereupon it was diluted with CH2CI2 and washed with 1 N HCI, sat. NaHCO3 and brine. The organic layer was dried, filtered and concentrated to provide 1.02 g of the crude product which was used in the following step with no further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In dimethyl sulfoxide; acetonitrile; at 80℃; for 72h; | Step A. tert-Butyl 3-[({10-[(2,2'-dimethyl-1,1'-biphenyl-4-yl)carbonyl]-10,1dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl}carbonyl)amino]methyl}piperidine-1-carboxylate To a suspension of 2,2,2-trichloro-1-{10-[(2,2'-dimethyl-1,1'-biphenyl-4-yl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl}ethanone of Example 9 (0.54 g, 1.0 mmol) and <strong>[162167-97-7]3-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester</strong> (0.43 g, 2.0 mmol) in dry acetonitrile (5 mL) was added dimethylsulfoxide (0.35 mL, 4.9 mmol) and the reaction mixture heated to 80° C. under nitrogen for 3 days. The cooled reaction mixture was diluted with dichloromethane (25 mL), washed with water (2*25 mL) and brine (25 mL), dried over anhydrous potassium carbonate, filtered and concentrated in vacuo to afford a brown oil (0.81 g). Purification by flash chromatography using a solvent gradient of 3 to 20percent ethyl acetate in dichloromethane gave the title compound (0.45 g) as a white foam. HRMS. Calcd for C39H45N4O4: 633.34354. Found [(+)ESI, m/z]: 633.34262. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
(Step 2) Synthesis of (2R)-N-(3-piperidylmethyl)-1-{(2S)-1-(3,3,3-triphenylpropanoyl)pyrrolidin-2-yl}carbonylpyrrolidine-2-carboxamide monohydrochloride The title compound was prepared by conducting procedures similar to Steps 5-6 of Example 1, using (2R)-1-{(2S)-1-(3,3,3-triphenylpropanoyl)pyrrolidin-2-yl}carbonylpyrrolidine-2-carboxylic acid and <strong>[162167-97-7]3-aminomethyl-1-(tert-butoxycarbonyl)piperidine</strong>. The compound was obtained as a white solid. 1H-NMR(CD3OD, deltappm): 1.10-2.16(15H, m), 2.34-2.53 (1H, m), 2.60-3.16(5H, m), 3.34-3.54(3H, m), 3.70-3.90(2H, m), 4.12-4.19(1H, m), 4.35-4.40(1H, m), 7.10-7.30(15H, m) FAB-MS(m/e, as (C37H44N4O3+H)+): 593 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
(Step 1) Synthesis of 3-amino-N-{(1-cyclohexylmethyl-3-piperidyl) methyl}propanamide The title compound was prepared by procedures similar to Steps 1-4 of Example 17, using <strong>[162167-97-7]3-aminomethyl-1-(tert-butoxycarbonyl)piperidine</strong>. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
7% | Example 40 (+-)-3-(4-Fluorophenyl)-1-(piperidin-3-yl)methyl-2-(pyridin-4-yl)-1 H -pyrrole (Compound No. 2-2520) In a similar manner to the procedures described in Examples 18(i) and 18(ii) above, reactions were carried out using (+-)-3-aminomethyl-(1-t-butoxycarbonyl)piperidine as a starting material instead of (+-)-3-amino-1-(t-butoxycarbonyl)pyrrolidine to give the title compound (total yield 7percent) as a white powder. Melting point 134 - 135°C 1H-Nuclear magnetic resonance spectrum (400 MHz, CDCl3) delta ppm: 8.59 (2H, doublet, J=6 Hz); 7.16 (2H, doublet, J=6 Hz); 7.06 (2H, doublet of doublets, J=9 Hz, 5 Hz); 6.88 (2H, triplet, J=9 Hz); 6.79 (1H, doublet, J=3 Hz); 6.34 (1H, doublet, J=3 Hz); 3.74 (2H, doublet, J=8 Hz); 2.94-2.87 (1H, multiplet); 2.83-2.73 (1H, multiplet); 2.46 (1H, doublet of doublets, J=12 Hz, 3 Hz); 2.13 (1H, doublet of doublets, J=12 Hz, 10 Hz); 1.75-1.51 (3H, multiplet); 1.40-1.28 (1H, multiplet); 0.98-0.85 (1H, multiplet). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Referential Example 7 Cyclopentylmethyl methanesulfonate The title compound was synthesised by a method similar to Step 4 of Referential Example 1, using cyclopentylmethanol. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Referential Example 4 3-Aminomethyl-1-(tert-butoxycarbonyl)piperidine The title compound was prepared by procedures similar to Steps 2-6 of Referential Example 1, using ethyl 3-piperidinecarboxylate. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 0 - 20℃; for 4h; | 2-(4-Chlorophenyl)-4-methylthiazole-5-carboxylic acid (507 mg, 2.00 mmol), 1-(tert-butoxycarbonyl)piperidin-3-yl methylamine (429 mg, 2.00 mmol) and 1-hydroxybenzotriazole monohydrate (368 mg, 2.40 mmol) were dissolved in N,N-dimethylformamide (10 mL). The mixture was chilled in an ice bath and 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (460 mg, 2.40 mmol) and N-methylmorpholine (0.528 mL, 4.80 mmol) were added. The mixture was then stirred at room temperature for 4 hours and a 5percent aqueous citric acid was added. This mixture was extracted with ethyl acetate and the extract was washed sequentially with a saturated aqueous sodium bicarbonate solution and brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 851 mg (95percent) of the desired compound as a colorless amorphous product. 1H NMR (400 MHz, CDCl3)delta 1.42-1.51 (11H, m), 1.60-1.72 (1H, m), 1.78-1.96 (2H, m), 2.75 (3H, s), 3.05-3.86 (6H, m), 6.59 (1H, brs), 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz). |
95% | With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 0 - 20℃; for 4h; | 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (507 mg, 2.00 mmol), 1-(tert-butoxycarbonyl)piperidin-3-yl methylamine (429 mg, 2.00 mmol) and 1-hydroxyberizotriazole monohydrate (368 mg, 2.40 mmol) were dissolved in N,N-dimethylformamide (10 mL). The solution was cooled in an ice bath and 3-(3-dimethylaminopropyl)-1-ethylcarbodiimidehydrochloride (460 mg, 2.40 mmol) and N-methylmorpholine (0.528 mL, 4.80 mmol) were added. The mixture was stirred at room temperature for 4 hours. Subsequently, a 5percent aqueous citric acid was added and the mixture was extracted with ethyl acetate. The extract was washed sequentially with a saturated aqueous sodium bicarbonate solution and a saturated brine, dried over magnesium sulfate and evaporated. Purification of the resulting residue by silica gel column chromatography (hexane:ethyl acetate = 10:1 --> 2:1) afforded the title compound as a colorless amorphous material (851 mg, 95 percent). 1H NMR (400 MHz, CDCl3) delta 1.42-1.51 (11H, m), 1.60-1.72 (1H, m), 1.78-1.96 (2H, m), 2.75 (3H, s), 3.05-3.86 (6H, m), 6.59 (1H, brs), 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate; In water; ethyl acetate; at 20℃; | Example 103; 2-(3-Fluoro-phenyl>pyrimidine-5-carboxylic acid (l-methanesulfonyl-piperidin-3-gammalmethyl)amide; Step 1; To a solution of potassium carbonate (13.94 mmol) and 3-aminomethyl-piperidine-l- carboxylic acid tert-butyl ester (4.65 mmol) in ethyl acetate (30 mL) and water (20 mL) is added a solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylicacid chloride (4.65 mmol) in ethyl acetate (20 mL). The mixture is stirred at room temperature overnight. The reaction mixture is extracted with ethyl acetate, washed with water, dried (Na2SC^) and concentrated in vacuo to give 3-([2-(3-fluoro- pheny)-pyrimidine-5-carbonyl]-amino}-methyl)-piperidine-l-carboxylic acid tert-butyl ester as a solid. MS 415 (M+H); 1HNMR(SOO MHz, CDCl3): delta 1.47 (s, 9H), 1.55-2.22 (m, 5H), 2.90-4.90 (m, 6H), 7.15-7.25 (m, H), 7.41-7.53 (m, H), 7.56 (bs, NH), 8.18 (d, H), 8.29 (d, H), 9.21 (s, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylsilane; sodium carbonate; trifluoroacetic acid; In dichloromethane; water; | EXAMPLE 274 N-[4-(4-amino-7-{(1Z)-3-oxo-3-[(3-piperidinylmethyl)amino]-1-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide A mixture of Example 270 (11 mg, 0.020 mmol), tert-butyl 3-(aminomethyl)-1-piperidinecarboxylate (5 mg, 0.024 mmol), and Na2CO3 (0.060 mmol, 6 mg) in dichloromethane (1 mL) and water (0.5 mL) was treated with a solution of tetramethylfluoroformadinium hexafluorophosphate (TFFH, 8 mg, 0.030 mmol) in dichloromethane (0.5 mL), stirred for 3 days at ambient temparature, treated with additional amine (12 mg, 0.056 mmol), stirred another day, treated with additional TFFH (30 mg, 0.11 mmol), and partitioned between dichloromethane and saturated NaHCO3. The combine organic phases were dried (Na2SO4), filtered, and concentrated. The residue was purified by reversed phase HPLC. The acetonitrile was removed under vacuum and the residue was lyophilized to provide the BOC-protected amine which was dissolved in dichloromethane (1 mL), triethylsilane (0.2 mL), and trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue was purified by reverse phase HPLC. The acetonitrile was removed under vacuum and the desired product was isolated by lyophylization (1.9 mg). LCMS m/e 595.2; Rt=2.67 min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
A mixture of EXAMPLE 7A (168.3 mg), <strong>[162167-97-7]tert-butyl 3-(aminomethyl)piperidine-1-carboxylate</strong> (107 mg), and N,N-diisopropylethylamine (450 muL) in acetonitrile (4.0 mL) was heated in a microwave reactor for 10 minutes at 50° C., and 20 minutes at 190° C., cooled, treated with tert-butyl pyrrolidin-3-ylcarbamate (112 mg), heated in a microwave reactor for 30 minutes at 100° C., cooled and concentrated. A solution of the concentrate in a mixture of tetrahydrofuran (2 mL) and methanol (1 mL) was treated with sodium hydroxide (2M, 800 muL), stirred for 4 hours at 50° C., cooled, concentrated, treated with water, acidified to pH 6 with 1M HCl, and filtered. The solid was treated with trifluoroacetic acid (2 mL), stirred for 2 hours at 25° C., and concentrated. The concentrate was purified by reverse phase high performance liquid chromatography (HPLC) on a C8 column with 10-100percent acetonitrile in water containing 0.1percent trifluoroacetic acid. NMR (300 MHz, DMSO-d6) delta ppm 8.94 (s, 1H), 8.80-8.67 (m, 1H), 8.44-8.16 (m, 4H), 8.10 (d, 1H), 4.46-4.34 (m, 2H), 4.08-3.82 (m, 4H), 3.28-3.10 (m, 2H), 2.86-2.67 (m, 2H), 2.44-2.26 (m, 2H), 2.19-2.06 (m, 1H), 1.87-1.20 (m, 4H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
23% | Step 4. Preparation of 6-[butvl(methvl)amino1-2-(2-methoxvphenvl)-3-(piperidin-3-vlmethvl)-quinazolin-4(3H)-one trifluoroacetate; [107] A solution of 6-[butyl(methyl)amino]-2-(2-methoxyphenyl)-4H-3,1-benzoxazin-4-one(200 mg, 0.59 mmol) (step 3) and <strong>[162167-97-7]tert-butyl 3-(aminomethyl)piperidine-1-carboxylate</strong> (152.0 mg,0.71 mmol) in CHCI3 (70 mL) was stirred at reflux for 2.5 days. tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate (50 mg, 0.51 mmol) was added, and the mixture was heated under refluxfor 10 h to form the uncyclized intermediate. 1,2-Ethanediol (2 mL) and NaOH (5.5 mg, 0.14mmol) were added, chloroform was removed in vacuo, and the resulting mixture was stirred at130°C for 3 h. More NaOH (15 mg, 0.38 mmol) was added, and the resulting mixture was stirredat 130°C for 15 h. To remove the BOC protecting group from the cyclized material, DCM (2 mL)was added, followed by TFA (1.35 g, 11.82 mmol). The mixture was stirred at rt for 3 h. Thevolatile solvents were removed, MeOH (2 mL) was added, and the mixture was purified on aGilson HPLC reversed-phase system eluting with the gradient 2-60percent MeCN/water (containing330.1percent TFA) to afford 78 mg (23percent) of the product as a clear, colorless oil. 1H NMR (300 MHz,CD3OD)67.71 (d, 1H), 8.18 (dd, 1H), 7.86-7.87 (m, 1H), 7.67 (dd, 1H), 7.53-7.61 (m, 1H), 7.20 (d,1H), 7.05-7.12 (m, 1H), 4.11 (s, 3H), 3.56-3.64 (m, 2H), 3.33-3.51 (m, 4H), 3.28 (s, 3H), 2.85-2.97(m, 1H), 2.73-2.84 (m, 1H), 2.06-2.22 (br m, 1H), 1.87-2.04 (m, 2H), 1.65-1.83 (m, 1H), 1.46-1.60(m, 2H), 1.29-1.45 (m, 3H), 0.93 (t, 3H); ES-MS m/z 435.3 (MH+); HPLC RT (min) 2.76. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃; for 24h; | (3) Synthesis of tert-Butyl 3-[(2-methoxy benzoyl)amino]methyl}piperidine-1-carboxylate HATU (293 mg, 0.77 mmol) was added to a DMF (3 mL) solution of the compound (150 mg, 0.7 mmol) synthesised in (2), 2-methoxybenzoic acid (117 mg, 0.77 mmol), and diisopropylethylamine (0.27 mL,1.54 mmol), and the mixture was stirred at room temperature for 24 hours. After adding ethyl acetate, the reaction mixture was washed twice with distilled water, and once with saturated brine. The organic layer was dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue was then purified using silica gel column chromatography to obtain the target (244 mg, 100percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With hydrazine hydrate; In ethanol; at 20℃; for 24h; | (2) Synthesis of tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate Hydrazine monohydrate (1 mL, 20.58 mmol) was added to an ethanol (20 mL) solution of the compound (1.45 g, 4.21 mmol) synthesised in (1), and the mixture was stirred at room temperature for 24 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was re-suspended in ethanol, and allowed to stand under ice-cooled conditions. After filtration, the filtrate was concentrated under reduced pressure to obtain the target (823 mg, 91 percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
To a solution of 5.1 (0.13 mmol) in DMF (1 mL) was added tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (0.15 mmol) and DIEA (0.2 mmol). After heating at 60 °C for 12 h, the solvent was removed in vacuo. TFA/CH2C12 (1 : 1) was added and stirred for 30 min. Solvent was removed in vacuo and the crude residue was purified by reverse- phase HPLC to provide title compound 5.2. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
200.13-[({4-[4-Fluoro-2-(trans-4-methoxy-cyclohexyloxy)-phenylamino]-5-methyl-thieno[2,3-d]pyrimidine-6-carbonyl}-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl esterPrepared analogously to 153.2 from 0.1 g compound 192.1 and 0.15 g <strong>[162167-97-7]3-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester</strong>.Yield: 0.119 g |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; | Example 113.2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (l-methanesulfonyl-piperidin-3- lmethyl)-amideStep 1A 10 mL round-bottomed flask was charged with 2-cyclopropyl-5-((2- (trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (250 mg, 0.75 mmol), 3-(aminomethyl)-l-N-Boc-piperidine (241 mg, 1.12 mmol), HOBT (111 mg, 0.82 mmol) and EDC (158 mg, 0.82 mmol). Then added DMF (3.3 mL) followed by N,N- diisopropylethylamine (0.20 mL, 1.12 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with H20 (5 mL) and extracted with Et20 (2 x 50 niL). The combined organic layers were washed twice with H20 and once with brine then dried over Na2S04, filtered and concentrated. The residue was purified by chromatography over 24g Si02 using EtOAc/Hexanes (gradient: 0-40percent EtOAc) to afford 393 mg (99percent) of 3- ({ [2-cyclopropyl-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7- carbonyl]-amino}-methyl)-piperidine-l-carboxylic acid tert-butyl ester as a pale yellow oil |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In tetrahydrofuran; | Formation of (R)-tert-butyl 3-((2-chloro-5-fluoropyrimidin-4-ylamino)methyl)-piperidine-1-carboxylate (11a)To a solution of 2,4-dichloro-5-fluoropyrimidine (0.43 g, 2.59 mmol) and (R)-<strong>[162167-97-7]tert-butyl 3-(aminomethyl)piperidine-1-carboxylate</strong> (0.56 g, 2.59 mmol) in THF (50 mL) was added iPr2NEt (0.45 mL, 2.59 mmol).The reaction mixture was heated at 80° C. at for 8 h.The solvent was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (5-30percent EtOAc/hexanes) to afford the desired product, 11a. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In dichloromethane; acetonitrile; | Example 6 Preparation of (S)-tert-butyl 3-((2-((Z)-(2,6-dimethylphenylimino)-((E)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazinyl)-methylthio)acetamido)methyl)piperidine-1-carboxylate (Compound 56C) (Synthesis Method E) To a solution of bromoacetyl bromide (26 microliters (muL), 0.299 mmol) in dichloroethane (3 mL) was added dropwise a solution of (S)-<strong>[162167-97-7]tert-butyl 3-(aminomethyl)piperidine-1-carboxylate</strong> (63.9 mg, 0.298 mmol) in dichloromethane (1 mL), followed by N-ethyl-N-isopropylpropan-2-amine (76 mg, 0.588 mmol). This mixture was stirred at room temperature for 30 min, then (E)-N-(2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazine-carbothioamide (100 mg, 0.196 mmol) was added as a solid and the mixture was heated to 40° C. for 90 min. It was then allowed to cool to room temperature and evaporated under reduced pressure, giving a light yellow glass, which was dissolved in acetonitrile (2 mL) and allowed to stand at room temperature. The resulting precipitate was isolated by centrifuge and decanting, washing with fresh acetonitrile. The solid was dried under a nitrogen stream and then under high vacuum. The crude product was recrystallized from acetone-isopropyl alcohol. The title compound was isolated as a white solid (36.5 mg, 24percent): mp 148-151° C.; 1H NMR (400 MHz, methanol-d4) delta 9.18 (s, 1H), 8.59 (s, 1H), 8.30 (d, J=8.1 Hz, 2H), 8.12 (m, 2H), 8.07-8.00 (m, 2H), 7.58-7.43 (m, 2H), 7.33 (dd, J=8.6, 6.5 Hz, 1H), 7.25 (d, J=7.6 Hz, 2H), 4.02 (m, 2H), 3.97-3.75 (m, 2H), 3.21 (d, J=6.9 Hz, 2H), 2.90 (m, 1H), 2.59 (m, 1H), 2.35 (s, 6H), 1.84 (m, 2H), 1.78-1.63 (m, 2H), 1.44 (s, 9H), 1.29 (m, 3H); ESIMS m/z 765 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In tetrahydrofuran; | Compounds DA-171 (70 mg, 0.370 mmol) and 31 -2 (79 mg, 0.370 mmol) were combined and THF (4 mL) was added. The resulting mixture was stirred overnight, then the solvent was stripped in vacuo and the boc protected product isolated by normal phase chromatography (DCM/MeOH, 0percent -> 10percent). The purified boc protected product was then dissolved in EtOH/HCI (5 mL) and the resulting solution stirred for 1 h. Diethyl ether (30 mL) was then added and the product collected by filtration as a white solid of 1 -((1 H- pyrrolo[2,3-b]pyridin-4-yl)methyl)-3-(piperidin-3-ylmethyl)thiourea. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
144 mg | With dicyclohexyl-(2?,4?,6?-triisopropyl-3,6-dimethoxy-[1,1?-biphenyl]-2-yl)phosphine; chloro[2-(dicyclohexylphosphino)-3 ,6-dimethoxy-2?,4?, 6?-triisopropyl- 1,1?-biphenyl] [2-(2-aminoethyl)phenyl]palladium(II); sodium t-butanolate; In 1,4-dioxane; at 110℃; for 2h;Inert atmosphere; Microwave irradiation; | Piperidin-3-ylmethyl-[2-(3,4,5-trimethoxy-phenyl)-furo[3,2-b]pyridin-7-yl]- amine ("A2") Under nitrogen atmosphere 7-Chloro-2-(3,4,5-trimethoxy-phenyl)-furo[3,2- b]pyridine (100 mg; 0,313 mmol), 2-(dicyclohexylphosphino)-3,6-dimethoxy- 2,,4',6'-triisopropyl-1,1,-biphenyl (2 mg; 0,003 mmol), chloro[2-(dicyclohexyl- phosphinoJ-S.e-dimethoxy^'^'^'-tri-i-propyl-l .l'-biphenylJp^-aminoethyl)- phenyl] palladium (II) (3 mg; 0,003 mmol) and sodium-tert-butylat (61 mg; 0,626 mmol) are dissolved in dry 1 ,4-dioxan (1 ,5 ml). 3-(Aminomethyl)-1 - Boc-piperidine (80 mg; 0,375 mmol) ias added to the mixture which is heated for 2 h at 110C in a microwave reactor. The mixture is evaporated in vacuo and the obtained residue is purified by flash chromatography (dichloro- methane / MeOH 9:1) to give 3-[2-(3,4,5-trimethoxy-phenyl)-furo[3,2- b]pyridin-7-ylamino]-methyl}-piperidine-1-carboxylic acid tert-butyl ester (144 mg; 0,289 mmol) as bright yellow solid. The solid is dissolved in 4M HCI in dioxan (5.7 ml) and stirred for 16 h. The precipitate is filtered off, washed with dioxane and dried for 16 h at 50 C to give 114 mg piperidin-3-ylmethyI- [2-(3,4,5-trimethoxy-phenyl)-furo[3,2-b]pyridin-7-yl]-amine as hydrochloride; HPLC: Rt 2.35 min; LCMS (ESI+) [M+H+] 398.2 m/z; H N R (400 MHz, DMSO-de) delta [ppm} 14.36 - 14.02 (m, 1H), 9.28 - 9.10 (m, 1H), 9.10 - 8.88 (m, 1 H), 8.79 - 8.58 (m, 1 H), 8.39 - 8.02 (m, 1 H), 7.69 (s, H), 7.47 (s, 2H), 7.04 - 6.84 (m, 1H), 3.93 (s, 7H), 3.75 (s, 3H), 3.57 (s, 2H), 3.27 - 3.12 (m, 2H), 2.75 (d, J = 11.4 Hz, 2H), 2.27 - 2.09 (m, 1 H), 1.97 - 1.74 (m, 2H), 1.74 - 1.54 (m, 1 H), 1.40 - 1.23 (m, 1 H). |
Tags: 162167-97-7 synthesis path| 162167-97-7 SDS| 162167-97-7 COA| 162167-97-7 purity| 162167-97-7 application| 162167-97-7 NMR| 162167-97-7 COA| 162167-97-7 structure
[ 1290046-61-5 ]
tert-Butyl 3-(1-aminopropyl)piperidine-1-carboxylate
Similarity: 0.98
[ 1235439-55-0 ]
tert-Butyl 3-(1-aminoethyl)piperidine-1-carboxylate
Similarity: 0.98
[ 236406-22-7 ]
1-Boc-4-(Aminomethyl)-4-methylpiperidine
Similarity: 0.98
[ 189333-03-7 ]
tert-Butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate
Similarity: 0.98
[ 138022-04-5 ]
tert-Butyl methyl(piperidin-4-ylmethyl)carbamate
Similarity: 0.98
[ 1290046-61-5 ]
tert-Butyl 3-(1-aminopropyl)piperidine-1-carboxylate
Similarity: 0.98
[ 1235439-55-0 ]
tert-Butyl 3-(1-aminoethyl)piperidine-1-carboxylate
Similarity: 0.98
[ 138022-04-5 ]
tert-Butyl methyl(piperidin-4-ylmethyl)carbamate
Similarity: 0.98
[ 138022-02-3 ]
tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate
Similarity: 0.98
[ 144222-22-0 ]
1-Boc-4-(Aminomethyl)piperidine
Similarity: 0.98
[ 1290046-61-5 ]
tert-Butyl 3-(1-aminopropyl)piperidine-1-carboxylate
Similarity: 0.98
[ 1235439-55-0 ]
tert-Butyl 3-(1-aminoethyl)piperidine-1-carboxylate
Similarity: 0.98
[ 236406-22-7 ]
1-Boc-4-(Aminomethyl)-4-methylpiperidine
Similarity: 0.98
[ 189333-03-7 ]
tert-Butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate
Similarity: 0.98
[ 138022-04-5 ]
tert-Butyl methyl(piperidin-4-ylmethyl)carbamate
Similarity: 0.98
[ 1290046-61-5 ]
tert-Butyl 3-(1-aminopropyl)piperidine-1-carboxylate
Similarity: 0.98
[ 1235439-55-0 ]
tert-Butyl 3-(1-aminoethyl)piperidine-1-carboxylate
Similarity: 0.98
[ 236406-22-7 ]
1-Boc-4-(Aminomethyl)-4-methylpiperidine
Similarity: 0.98
[ 189333-03-7 ]
tert-Butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate
Similarity: 0.98
[ 138022-04-5 ]
tert-Butyl methyl(piperidin-4-ylmethyl)carbamate
Similarity: 0.98
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :